Reactogenicity of a three-dose pertussis acellular vaccine catch-up in children 21-40 months of age

被引:4
作者
degli Atti, MC
Anemona, A
Tozzi, AE
Stefanelli, P
Giammanco, A
Salmaso, S
机构
[1] Ist Super Sanita, Epidemiol & Biostat Lab, Reparto Malattie Infett, I-00161 Rome, Italy
[2] Ist Super Sanita, Lab Bacteriol & Med Micol, Reparto Malattie Infett, I-00161 Rome, Italy
[3] Univ Palermo, Dept Hyg & Microbiol, Palermo, Italy
关键词
acellular pertussis vaccines; catch-up; safety;
D O I
10.1016/S0264-410X(98)00405-8
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The reactogenicity of a three-dose catch-up acellular pertussis (aP) immunization of children at 21-40 months of age was evaluated. Vaccination was well-tolerated: fever greater than or equal to 38 degrees C was reported after 5% of administered doses and local reactions after 14-15%. The onset of adverse events was not associated with age at vaccination, interval between doses or previous presence of antibodies against pertussis, whereas injection in sites other than the buttock and presence of the same symptom after a previous dose were associated with higher reactogenicity. Because of the good safety profile of primary aP immunization in children > 1 year of age, catch-up vaccination campaigns could be considered in areas where pertussis whole-cell vaccination uptake has been low and where the number of susceptible children should be reduced to control pertussis circulation. (C) 1999 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:2030 / 2035
页数:6
相关论文
共 18 条
  • [1] *ADV COMM IMM PRAC, 1997, MMWR-MORBID MORTAL W, V46, pRR7
  • [2] CLINICAL REACTIONS AND IMMUNOGENICITY OF THE BIKEN ACELLULAR DIPHTHERIA AND TETANUS TOXOIDS AND PERTUSSIS-VACCINE IN 4-YEAR-OLD THROUGH 6-YEAR-OLD UNITED-STATES CHILDREN
    BERNSTEIN, HH
    ROTHSTEIN, EP
    PICHICHERO, ME
    FRANCIS, AB
    KOVEL, AJ
    DISNEY, FA
    GREEN, JL
    MARSOCCI, SM
    LYND, AM
    WOOD, GC
    SCHILLER, RP
    GIRONE, JAC
    HIPP, TJ
    SOUDER, RL
    KENNEDY, TI
    MESCHIEVITZ, CK
    [J]. AMERICAN JOURNAL OF DISEASES OF CHILDREN, 1992, 146 (05): : 556 - 559
  • [3] BINKIN N, 1994, B WORLD HEALTH ORGAN, V72, P885
  • [4] BINKIN NJ, 1992, PEDIATR INFECT DIS J, V11, P653
  • [5] DELORIA MA, 1995, PEDIATRICS, V96, P592
  • [6] FLEISS JL, 1981, STAT METH RAT PROP
  • [7] Impact of anti-vaccine movements on pertussis control: the untold story
    Gangarosa, EJ
    Galazka, AM
    Wolfe, CR
    Phillips, LM
    Gangarosa, RE
    Miller, E
    Chen, RT
    [J]. LANCET, 1998, 351 (9099) : 356 - 361
  • [8] GIAMMANCO A, 1991, REV INFECT DIS, V13, P1216
  • [9] A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis
    Greco, D
    Salmaso, S
    Mastrantonio, P
    Giuliano, M
    Tozzi, AE
    Anemona, A
    Atti, MLCD
    Giammanco, A
    Panei, P
    Blackwelder, WC
    Klein, DL
    Wassilak, SGF
    Stefanelli, P
    Bottone, M
    Sofia, T
    Luzi, S
    Bellomi, G
    Cobianchi, F
    Canganella, G
    Meduri, F
    Scuderi, G
    Chiarini, A
    Maggio, M
    Taormina, S
    Genovese, M
    Moiraghi, A
    Barale, A
    DiTommaso, S
    Malaspina, S
    Vasile, E
    Ferraro, P
    DalLago, P
    DeMarzi, L
    Robino, L
    Giraldo, E
    Coppola, N
    Materassi, P
    Castellani, GT
    Basso, F
    Barbuti, S
    Quarto, M
    Lopalco, P
    DOrazio, P
    Sanguedolce, A
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (06) : 341 - 348
  • [10] A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine
    Gustafsson, L
    Hallander, HO
    Olin, P
    Reizenstein, E
    Storsaeter, J
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (06) : 349 - 355